201 related articles for article (PubMed ID: 29453624)
1. Hydroxyurea responses in clinically varied beta, HbE-beta thalassaemia and sickle cell anaemia patients of Eastern India.
Chatterjee T; Chakravarty A; Chakravarty S
Ann Hematol; 2018 May; 97(5):893-898. PubMed ID: 29453624
[TBL] [Abstract][Full Text] [Related]
2. Effect of hydroxyurea on the transfusion requirements in patients with severe HbE-beta-thalassaemia: a genotypic and phenotypic study.
Italia KY; Jijina FF; Merchant R; Panjwani S; Nadkarni AH; Sawant PM; Nair SB; Ghosh K; Colah RB
J Clin Pathol; 2010 Feb; 63(2):147-50. PubMed ID: 20154037
[TBL] [Abstract][Full Text] [Related]
3. Alpha Globin Gene Mutation: A Major Determinant of Hydroxyurea Response in Transfusion-Dependent HbE-β-Thalassaemia.
Biswas S; Ray R; Roy K; Bandyopadhyay A; Ghosh K; Bhattacharyya M
Acta Haematol; 2019; 142(3):132-141. PubMed ID: 31352439
[TBL] [Abstract][Full Text] [Related]
4. Genetic determinants related to pharmacological induction of foetal haemoglobin in transfusion-dependent HbE-β thalassaemia.
Biswas S; Nag A; Ghosh K; Ray R; Roy K; Bandyopadhyay A; Bhattacharyya M
Ann Hematol; 2019 Feb; 98(2):289-299. PubMed ID: 30413899
[TBL] [Abstract][Full Text] [Related]
5. On the use of hydroxyurea/erythropoietin combination therapy for sickle cell disease.
el-Hazmi MA; al-Momen A; Kandaswamy S; Huraib S; Harakati M; al-Mohareb F; Warsy AS
Acta Haematol; 1995; 94(3):128-34. PubMed ID: 7502628
[TBL] [Abstract][Full Text] [Related]
6. Sickle cell disease in Madhya Pradesh, Central India: A comparison of clinical profile of sickle cell homozygote vs. sickle-beta thalassaemia individuals.
Yadav R; Lazarus M; Ghanghoria P; Singh M; Gupta RB; Kumar S; Sharma RK; Shanmugam R
Hematology; 2016 Oct; 21(9):558-63. PubMed ID: 27077770
[TBL] [Abstract][Full Text] [Related]
7. Genetic Blood Disorders Survey in the Sultanate of Oman.
Al-Riyami A; Ebrahim GJ
J Trop Pediatr; 2003 Jul; 49 Suppl 1():i1-20. PubMed ID: 12934793
[TBL] [Abstract][Full Text] [Related]
8. Hydroxyurea in sickle cell disease--a study of clinico-pharmacological efficacy in the Indian haplotype.
Italia K; Jain D; Gattani S; Jijina F; Nadkarni A; Sawant P; Nair S; Mohanty D; Ghosh K; Colah R
Blood Cells Mol Dis; 2009; 42(1):25-31. PubMed ID: 18954999
[TBL] [Abstract][Full Text] [Related]
9. Drug Repurposing: Hydroxyurea Therapy Improves the Transfusion-Free Interval in HbE/Beta-Thalassemia-Major Patients with the
Ghosh D; Panja A; Saha D; Banerjee U; Datta AK; Basu A
Genet Test Mol Biomarkers; 2021 Aug; 25(8):563-570. PubMed ID: 34406845
[No Abstract] [Full Text] [Related]
10. Fetal haemoglobin augmentation in E/beta(0) thalassaemia: clinical and haematological outcome.
Singer ST; Kuypers FA; Olivieri NF; Weatherall DJ; Mignacca R; Coates TD; Davies S; Sweeters N; Vichinsky EP;
Br J Haematol; 2005 Nov; 131(3):378-88. PubMed ID: 16225658
[TBL] [Abstract][Full Text] [Related]
11. Response to hydroxyurea among Kuwaiti patients with sickle cell disease and elevated baseline HbF levels.
Adekile A; Menzel S; Gupta R; Al-Sharida S; Farag A; Haider M; Akbulut N; Mustafa N; Thein SL
Am J Hematol; 2015 Jul; 90(7):E138-9. PubMed ID: 25851995
[No Abstract] [Full Text] [Related]
12. A randomised double-blind placebo-controlled clinical trial of oral hydroxyurea for transfusion-dependent β-thalassaemia.
Yasara N; Wickramarathne N; Mettananda C; Silva I; Hameed N; Attanayaka K; Rodrigo R; Wickramasinghe N; Perera L; Manamperi A; Premawardhena A; Mettananda S
Sci Rep; 2022 Feb; 12(1):2752. PubMed ID: 35177777
[TBL] [Abstract][Full Text] [Related]
13. Neonatal Screening and the Clinical Outcome in Children with Sickle Cell Disease in Central India.
Upadhye DS; Jain DL; Trivedi YL; Nadkarni AH; Ghosh K; Colah RB
PLoS One; 2016; 11(1):e0147081. PubMed ID: 26785407
[TBL] [Abstract][Full Text] [Related]
14. Response to hydroxyurea in beta thalassemia major and intermedia: experience in western India.
Italia KY; Jijina FJ; Merchant R; Panjwani S; Nadkarni AH; Sawant PM; Nair SB; Ghosh K; Colah RB
Clin Chim Acta; 2009 Sep; 407(1-2):10-5. PubMed ID: 19545554
[TBL] [Abstract][Full Text] [Related]
15. Hydroxyurea (hydroxycarbamide) for transfusion-dependent β-thalassaemia.
Ansari SH; Lassi ZS; Khowaja SM; Adil SO; Shamsi TS
Cochrane Database Syst Rev; 2019 Mar; 3(3):CD012064. PubMed ID: 30882896
[TBL] [Abstract][Full Text] [Related]
16. [Thalassemia and sickle-cell disease in Norway].
Graesdal JS; Gundersen K; Holm B; Waage A
Tidsskr Nor Laegeforen; 2001 Feb; 121(6):678-80. PubMed ID: 11293347
[TBL] [Abstract][Full Text] [Related]
17. Alpha-thalassaemia and response to hydroxyurea in sickle cell anaemia.
Darbari DS; Nouraie M; Taylor JG; Brugnara C; Castro O; Ballas SK
Eur J Haematol; 2014 Apr; 92(4):341-5. PubMed ID: 24330217
[TBL] [Abstract][Full Text] [Related]
18. A comprehensive review of hydroxyurea for β-haemoglobinopathies: the role revisited during COVID-19 pandemic.
Yasara N; Premawardhena A; Mettananda S
Orphanet J Rare Dis; 2021 Mar; 16(1):114. PubMed ID: 33648529
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of oral hydroxyurea in transfusion-dependent β-thalassaemia: a protocol for randomised double-blind controlled clinical trial.
Yasara N; Wickramarathne N; Mettananda C; Manamperi A; Premawardhena A; Mettananda S
BMJ Open; 2020 Oct; 10(10):e041958. PubMed ID: 33109679
[TBL] [Abstract][Full Text] [Related]
20. Sickle Cell Disease in Central India: A Potentially Severe Syndrome.
Jain D; Warthe V; Dayama P; Sarate D; Colah R; Mehta P; Serjeant G
Indian J Pediatr; 2016 Oct; 83(10):1071-6. PubMed ID: 27053181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
